A total of 221 new drugs for diabetes and related diseases are awaiting FDA approval or are in clinical studies, according to a report from the Pharmaceutical Research and Manufacturers of America. The treatments include 130 for type 2 diabetes, 32 for type 1 diabetes, 14 for unspecified diabetes and 64 for related conditions, with some medications in multiple categories.

Full Story:
PharmaTimes (U.K.)

Related Summaries